The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders.
Stahl
Stephen M
SM
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA. vj@mblcommunications.com
Wise
Dana D
DD
D000818:Animals; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D001931:Brain Mapping; D015897:Comorbidity; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009415:Nerve Net / Q000187:drug effects / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000502:physiology; D013315:Stress, Psychological / Q000150:complications* / Q000503:physiopathology; D000099052:CRF Receptor, Type 1
D018377:Neurotransmitter Agents; D011619:Psychotropic Drugs; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1